Story at a glance:
- The antiviral drug remdesivir, brand name Veklury, is approved for use against COVID-19 despite research showing it lacks effectiveness and can cause high rates of organ failure.
- John Beaudoin is calling for a criminal investigation into remdesivir, citing data that it may have killed 100,000 people in the U.S.
- Beaudoin received all the death certificates in Massachusetts from 2015 to 2022, finding 1,840 excess deaths from acute renal failure from Jan. 1, 2021, to Nov. 30, 2022, which he believes may be due to remdesivir.
- A study published in The Lancet found “no clinical benefit” from the use of remdesivir in hospitalized patients.
- The U.S. government pays hospitals a 20% upcharge on the entire hospital bill when remdesivir is used.
The U.S. Food and Drug Administration (FDA) authorized the experimental antiviral drug remdesivir, brand name Veklury, for emergency use against COVID-19 in May 2020.
By October 2020, it had received full approval. It remains a primary treatment for COVID-19 in hospitals, despite research showing it lacks effectiveness and can cause high rates of organ failure….